PlainRecalls
FDA Drug Moderate Class II Terminated

Glimepiride, USP, 4 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0250-30; b) 90-count bottle, NDC 61919-0250-90 Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Reported: April 5, 2023 Initiated: March 13, 2023 #D-0482-2023

Product Description

Glimepiride, USP, 4 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0250-30; b) 90-count bottle, NDC 61919-0250-90 Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Reason for Recall

cGMP deviations

Details

Recalling Firm
Direct Rx
Units Affected
30 count: 7 bottles; 90 count: 395 bottles
Distribution
Nationwide in the USA
Location
Dawsonville, GA

Frequently Asked Questions

What product was recalled?
Glimepiride, USP, 4 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0250-30; b) 90-count bottle, NDC 61919-0250-90 Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534. Recalled by Direct Rx. Units affected: 30 count: 7 bottles; 90 count: 395 bottles.
Why was this product recalled?
cGMP deviations
Which agency issued this recall?
This recall was issued by the FDA Drug on April 5, 2023. Severity: Moderate. Recall number: D-0482-2023.